Companies › Arcturus Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 2; Metabolic and endocrine, Respiratory; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ARCT-032 CFTR mRNA formulated in lipid nanoparticles | CFTR | Phase 2 | Cystic Fibrosis | Jun 2027 |
| ARCT-810 Ornithine Transcarbamylase (OTC) mRNA in lipid nanoparticle formulation | OTC | Phase 2 | OTC Deficiency | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06488313 | ARCT-810 | Phase 2 | OTC Deficiency | Metabolic and endocrine | Jun 2026 |
| NCT06747858 | ARCT-032 | Phase 2 | Cystic Fibrosis | Respiratory | Jun 2027 |
Cash of $185m on 2026-09-30; operating cash outflow about $62m a year; runway about 36 months at that burn, to Sep 2029; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Mannkind Mediar Therapeutics Shanghai Novamab Biopharmaceuticals Blue Blood Biotech Hangzhou Sciwind Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.